Prevention and treatment of degenerative changes in ocular surface epithelium in patients with dry eye syndrome

Brzheskiy, V.V.; Popov, V. Yu.; Калинина, Н. М.; Brzheskaya, I.V.

doi:10.17116/oftalma2018134051126

Cited by 14 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Метаболическая терапия у пациентов с НК осуществляется путем применения стимуляторов репаративной регенерации (декспантенол), назначения глазных капель и мазей с витаминами А (обеспечивает дифференциацию бокаловидных клеток конъюнктивы), В 12 (с антиоксидантным эффектом) и др. [22][23][24].…”

Section: резюме _____________________________________________________...unclassified

Recombinant Human Nerve Growth Factor in the Treatment of Neurotrophic Keratitis (Clinical Cases)

Ефимова,

Бржеский,

Кумыкова

2024

Офтальмология. Восточная Европа

View full text Add to dashboard Cite

На сегодняшний день нарушения чувствительной и трофической иннервации роговицы с развитием нейротрофической кератопатии (НК) отмечают не только при различных заболеваниях и повреждениях органа зрения, но и при системных заболеваниях, а также при различных поражениях головного мозга. В патогенезе НК важную роль играет нарушение правильного взаимодействия между эпителием и нервами роговицы. Клинические проявления НК весьма разнообразны. Основную роль в диагностике НК играет определение чувствительности роговицы и оценка прокрашивания глазной поверхности витальными красителями (раствор флюоресцеина). Традиционная консервативная терапия нейротрофической кератопатии включает слезозаместительную терапию, инстилляции препаратов аутокрови пациента и др. Отсутствие эффекта от консервативной терапии служит показанием к хирургическим методам лечения пациентов с НК (окклюзия слезных точек, тарзорафия, перевязка слезного канальца, трансплантация амниотической мембраны, биологическое пломбирование язвенного дефекта роговицы конъюнктивой, теноновой оболочкой, тканевыми клеями и др., лечебная кератопластика). Однако наибольшую патогенетическую ориентацию имеют инстилляции препарата фактора роста нервов (ФРН) человека (глазные капли ценегермин). ФРН, воздействуя на пострадавшие нервные волокна, стимулируют регенерацию нервных и эпителиальных клеток роговицы. Представленные в работе клинические случаи иллюстрируют эффективность терапии нейротрофического кератита у детей препаратом ценегермин. To date, impairments of sensitive and trophic innervation of the cornea with the development of neurotrophic keratopathy (NK) are noted not only in various diseases and injuries of the eye, but also in systemic diseases and in some brain lesions. The interact between the epithelium and corneal nerves is very important in the pathogenesis of NK. Сlinical manifestations of NK are quite diverse. The main ways of diagnostics of NK are quantitative evaluation of decreased corneal sensation and corneal staining with vital dye (Sodium Fluorescein). Traditional conservative treatment of neurotrophic keratopathy includes tear replacement therapy and instillations of autologous blood-derived serum eye drops. Lack of effect from conservative treatment is an indication for transition to surgical methods of treatment of patients with NK (lacrimal punctal occlusion; tarsorrhaphy; canalicular ligation; amniotic membrane transplantation; conjunctival flap transplantation, Tenon’s patch graft; gluing by tissue adhesives; therapeutic penetrating keratoplasty, etc.). However, the most pathogenetically oriented treatment method is therapy by instillation of Topical Recombinant Human Nerve Growth Factor (Cenegermin). NGF directly stimulates nerve fiber growth and regenerates the corneal epithelium. The clinical cases presented in this work allow us to evaluate Cenegermin’s effectiveness in treating neurotrophic keratitis in children.

show abstract

Section: резюме _____________________________________________________...unclassified

Recombinant Human Nerve Growth Factor in the Treatment of Neurotrophic Keratitis (Clinical Cases)

Ефимова,

Бржеский,

Кумыкова

2024

Офтальмология. Восточная Европа

View full text Add to dashboard Cite

show abstract

“…Dexpanthenol plays an important role in healing of the conjunctival and corneal epithelial damage. Due to its hygroscopic structure, it prevents dryness and maintains the integrity of the ocular surface [13].…”

Section: Role Of Dexpanthenol In Ophthalmologymentioning

confidence: 99%

Dexpanthenol in the treatment of corneal disorders and injuries

Szumny

Misiuk-Hojło²

2022

Ophthatherapy

View full text Add to dashboard Cite

Dexpanthenol – a precursor to vitamin B5 – is a compound of natural origin that has a long-known beneficial effect on skin and mucous membrane hydration and epithelial healing. Its anti-inflammatory activity is also used in treatment. Its effects on superficial tissues have been observed in numerous in vitro and in vivo studies, but the exact mechanism of action has not yet been understood. In ophthalmology, dexpanthenol is a well-known and widely used drug in patients with acute and chronic diseases of the ocular surface, as well as for treating the sequelae of corneal injuries.

show abstract

“…Since pharmaceutical companies have invented ophthalmic products containing dexpanthenol, they are now used in many ophthalmology departments to take advantage from their epithelial healing effect on the corneal epithelium layer [8][9][10][11]. After administration of dexpanthenol to an epithelial surface it is absorbed easily because of its alcoholic structure [12].…”

Section: Introductionmentioning

confidence: 99%

Travmatik korneal abrazyon hastalarında Dekspantenol kullanımının hasta konforuna olan etkisi

Kılıç¹,

Vural²,

Albayrak

et al. 2020

Pamukkale Medical Journal

View full text Add to dashboard Cite

The aim in this study was to investigate if the use of dexpanthenol could play a role in the relief of pain in the treatment of corneal abrasions (CA). Materials and methods: Patients presenting to the ophthalmology department and had a diagnosis of CA were conducted in this retrospective, case-control study. A detailed ocular examination was done and pain severity was assessed using a visual analogue scale (VAS) score. In group 1, subjects were treated with only topical ofloxacin 0.3% while subjects in group 2 were treated with topical ofloxacin 0.3% and dexpanthenol. Foreign body sensation, photophobia, excessive lacrimation and VAS were documented on the first, third and seventh days of follow up examinations. Results: 70 patients were allocated into group 1 and 68 patients were allocated into group 2. There were significant differences in VAS scores between the groups on the first, third and seventh days of follow up (p=0.002, p<0.001 and p<0.001, respectively). VAS scores were lower in group-2. There were no statistically significant differences between two groups in terms of photophobia, foreign body sensation, excessive lacrimation (p>0.05). All patients were free of any complications. Conclusion:Although it was shown that adding topical dexpanthenol to the treatment regimen could permit faster pain relief in treating CAs, the prospective studies should be done.

show abstract

Prevention and treatment of degenerative changes in ocular surface epithelium in patients with dry eye syndrome

Cited by 14 publications

References 26 publications

Recombinant Human Nerve Growth Factor in the Treatment of Neurotrophic Keratitis (Clinical Cases)

Recombinant Human Nerve Growth Factor in the Treatment of Neurotrophic Keratitis (Clinical Cases)

Dexpanthenol in the treatment of corneal disorders and injuries

Travmatik korneal abrazyon hastalarında Dekspantenol kullanımının hasta konforuna olan etkisi

Contact Info

Product

Resources

About